<DOC>
	<DOCNO>NCT00004243</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness docetaxel oxaliplatin treat patient metastatic recurrent solid tumor .</brief_summary>
	<brief_title>Docetaxel Oxaliplatin Treating Patients With Metastatic Recurrent Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose docetaxel follow oxaliplatin patient metastatic recurrent solid tumor . II . Describe toxicity regimen patient population dose level study . III . Evaluate pharmacokinetics pharmacodynamics regimen patient . OUTLINE : This dose escalation study docetaxel . Patients receive docetaxel IV 1 hour follow oxaliplatin IV 2 hour day 1 every 3 week . Treatment continue absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow disease progression . PROJECTED ACCRUAL : A total 15-20 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic recurrent solid tumor fail standard therapy standard therapy exist No known brain metastasis carcinomatosis meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 OR Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal : Creatinine great 1.25 time ULN Calcium great 12 mg/dL Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence neuropathy No history allergy platinum compound No history allergy antiemetic appropriate administration conjunction protocol direct chemotherapy No uncontrolled concurrent illness ( e.g. , ongoing active infection ) No medical , social , psychological factor would preclude consent follow PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : Prior chemotherapy , include fluorouracil cisplatin , allow At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Recovered prior surgery Other : At least 30 day since prior investigational drug No concurrent investigational commercial agent therapies No concurrent antiretroviral therapy ( HAART )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>